ResearcherTaipei Medical UniversityNo recent work listed

Fu-Ling Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6711-5820; OpenAlex author ID A5063714867. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 2 papers

Papers 2

An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. Co-author DOI 10.1016/j.bbrc.2023.149214 ↗
Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment. Co-author DOI 10.1016/j.heliyon.2023.e21774 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yu‐Ching Lee · 2 shared papers, 2023 · strength 0.41
- Paper An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. DOI 10.1016/j.bbrc.2023.149214 ↗
- Paper Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment. DOI 10.1016/j.heliyon.2023.e21774 ↗
Shiow‐Lin Pan · 1 shared paper, 2023 · strength 0.20
- Paper An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment. DOI 10.1016/j.bbrc.2023.149214 ↗
Shiow-Lin Pan · 1 shared paper, 2023 · strength 0.20
- Paper Effectiveness of anti-erythropoietin producing Hepatocellular receptor Type-A2 antibody in pancreatic cancer treatment. DOI 10.1016/j.heliyon.2023.e21774 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.